SUVN-507

SUVN-507 is a potent, selective, and orally bioavailable 5-HT6 receptor antagonist developed by Suven Life Sciences for the treatment of cognitive disorders. By antagonizing the 5-HT6 receptor, the compound facilitates the release of neurotransmitters such as acetylcholine, glutamate, and norepinephrine in the hippocampus and prefrontal cortex, regions of the brain essential for memory and executive function. SUVN-507 is being investigated for its potential to treat cognitive impairment associated with Alzheimer's disease and schizophrenia. It has successfully completed Phase 1 clinical trials, demonstrating a favorable safety and tolerability profile in human subjects, and is positioned as a follow-on or alternative to other 5-HT6 antagonists in the Suven pipeline.